| Christopher Pascual, PT, DPT | |
|
480 4th Ave Ste 301, Chula Vista, CA 91910-4403 | |
| (619) 409-3690 | |
| (619) 409-3695 |
| Full Name | Christopher Pascual |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 480 4th Ave Ste 301, Chula Vista, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093328064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 298108 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| William C Eves M D Inc | 4880892314 | 6 |
News Archive
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.
As research into COVID-19 swells, R&D on other infectious diseases is seriously lacking, report finds.
Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
› Verified 5 days ago
| Provider Name | Water And Sports Physical Therapy Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1699840934 PECOS PAC ID: 2365433232 Enrollment ID: O20100519000835 |
News Archive
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.
As research into COVID-19 swells, R&D on other infectious diseases is seriously lacking, report finds.
Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
› Verified 5 days ago
| Provider Name | William C Eves M D Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1285798033 PECOS PAC ID: 4880892314 Enrollment ID: O20170217001292 |
News Archive
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.
As research into COVID-19 swells, R&D on other infectious diseases is seriously lacking, report finds.
Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
› Verified 5 days ago
| Provider Name | California Luna Care Physical Therapy Pc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1689162166 PECOS PAC ID: 9638427834 Enrollment ID: O20180803002123 |
News Archive
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.
As research into COVID-19 swells, R&D on other infectious diseases is seriously lacking, report finds.
Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Pascual, PT, DPT 480 4th Ave Ste 301, Chula Vista, CA 91910-4403 Ph: (619) 409-3690 | Christopher Pascual, PT, DPT 480 4th Ave Ste 301, Chula Vista, CA 91910-4403 Ph: (619) 409-3690 |
News Archive
Healthy white blood cells, called "T-cells," play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists Zhi Zhang Yang, M.D., and Stephen Ansell, M.D., Ph.D., that was published in Cell Reports.
As research into COVID-19 swells, R&D on other infectious diseases is seriously lacking, report finds.
Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.
Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy.
› Verified 5 days ago
Nicole M Irizarry, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 510 E Naples St, Chula Vista, CA 91911 Phone: 619-421-6083 | |
Joseph Edward Bailey, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 955 Lane Ave, #201, Chula Vista, CA 91914 Phone: 619-421-9521 Fax: 619-421-9568 | |
Daniel Tucker, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 344 F St, Suite 300, Chula Vista, CA 91910 Phone: 619-585-4080 Fax: 619-427-4572 | |
Dr. Stacy Haller, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1040 Tierra Del Rey Ste 107, Chula Vista, CA 91910 Phone: 619-500-5884 | |
David Sebastian Mignea, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 320 Broadway Ste 2, Chula Vista, CA 91910 Phone: 619-422-0404 Fax: 619-422-4153 | |
Ms. Kara W. Barnett, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 891 Kuhn Dr, Ste. 101, Chula Vista, CA 91914 Phone: 619-656-6470 Fax: 619-656-6614 | |
Mrs. Afsoon Roshan Johnston, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 251 Landis Ave, Chula Vista, CA 91910 Phone: 619-498-8450 |